GlassScriptPhysician profile
John P Welch
NPI 1588629042
$3,702.43
in general payments reported to CMS, 2019-2025
34 companies · $98.59 in 2025
The $98.59 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,404 · 2020: $294 · 2021: $1,061 · 2022: $573 · 2023: $136 · 2024: $135 · 2025: $98.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $369.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $462.35 | 2019-2025 | Ozempic |
| Abbvie INC. | $417.11 | 2019-2023 | Vraylar |
| Lilly USA, LLC | $344.79 | 2019-2024 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $316.05 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $226.60 | 2019-2022 | |
| Pfizer INC. | $143.68 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $141.50 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $132.35 | 2019-2022 | |
| Amarin Pharma, INC. | $131.34 | 2019-2022 | |
| Amgen INC. | $110.17 | 2019-2022 | |
| Genentech USA, INC. | $85.49 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $84.73 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.58 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $81.62 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $79.66 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $73.59 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $73.17 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $73.01 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $71.41 | 2022 | |
| Axsome Therapeutics, INC. | $62.30 | 2024-2025 | Auvelity, Symbravo |
| Bayer Healthcare Pharmaceuticals INC. | $54.24 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $53.76 | 2021 | |
| Daiichi Sankyo INC. | $51.96 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.71 | 2021-2024 | Jardiance |
| Astellas Pharma US INC | $46.82 | 2019-2021 | |
| Sanofi Pasteur INC. | $44.52 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $35.24 | 2020-2021 | |
| Dexcom, INC. | $33.39 | 2021 | |
| Allergan, INC. | $31.50 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $23.57 | 2020 | |
| Abbott Laboratories | $23.49 | 2021 | |
| Ironshore Pharmaceuticals INC. | $22.57 | 2019 | |
| Clarus Therapeutics INC. | $22.31 | 2021 | |
| Mannkind Corporation | $13.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Welch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.